Open-label extension period results indicate Tulisokibart improves efficacy in Crohn's disease, suggesting a potential long-term treatment option.
Introduction: Tumor necrosis factor–like cytokine 1A (TL1A) is a mediator of inflammation and fibrosis in CD. Tulisokibart, an anti-TL1A monoclonal antibody, demonstrated robust efficacy without adverse safety signals during the 12-week induction period in adults with moderately to severely active CD in the multicenter, open-label, phase 2a APOLLO-CD study.
No takes yet. Share an insight, caveat, or question.
Soßdorf et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: